89bio Inc (ETNB) - Total Assets
Based on the latest financial reports, 89bio Inc (ETNB) holds total assets worth $603.49 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ETNB book value for net asset value and shareholders' equity analysis.
89bio Inc - Total Assets Trend (2018–2024)
This chart illustrates how 89bio Inc's total assets have evolved over time, based on quarterly financial data.
89bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
89bio Inc's total assets of $603.49 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how 89bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of 89bio Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 89bio Inc's current assets represent 99.5% of total assets in 2024, unchanged from 99.5% in 2018.
- Cash Position: Cash and equivalents constituted 26.3% of total assets in 2024, down from 98.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
89bio Inc Competitors by Total Assets
Key competitors of 89bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
89bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.19 | 13.92 | 23.61 |
| Quick Ratio | 15.19 | 14.39 | 23.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $561.91 Million | $538.20 Million | $213.11 Million |
89bio Inc - Advanced Valuation Insights
This section examines the relationship between 89bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.22 |
| Latest Market Cap to Assets Ratio | 4.60 |
| Asset Growth Rate (YoY) | -19.7% |
| Total Assets | $478.69 Million |
| Market Capitalization | $2.20 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values 89bio Inc's assets at a significant premium (4.60x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: 89bio Inc's assets decreased by 19.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 89bio Inc (2018–2024)
The table below shows the annual total assets of 89bio Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $478.69 Million | -19.72% |
| 2023-12-31 | $596.27 Million | +202.95% |
| 2022-12-31 | $196.82 Million | +21.18% |
| 2021-12-31 | $162.42 Million | -23.05% |
| 2020-12-31 | $211.07 Million | +120.90% |
| 2019-12-31 | $95.55 Million | +740.47% |
| 2018-12-31 | $11.37 Million | -- |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more